Psilocybin, the active compound in 'magic mushrooms,' shows strong therapeutic potential for treating alcohol use disorder (AUD) through psilocybin-assisted psychotherapy (PAP). A literature review of peer-reviewed studies from 2010 onward identified three principal pathways for its effects: neurobiological alterations (such as neuroplastic changes), behavioral and psychological improvements (including increased receptivity to cognitive therapies), and spiritual development (spiritual experiences that improve abstinence). The review supports the use of psilocybin in clinical AUD treatment but notes limitations, such as predisposition to certain mental illnesses. Further research and clinical trials are needed to establish a larger evidence base.
A systematic review of seven studies found that moderate to high doses of psilocybin therapy reduced depression symptoms in people with major depressive disorder. Single moderate doses (15±5 mg/70 kg) lessened depression, while high doses (25±5 mg/70 kg) produced greater improvements and minimal side effects. A positive link emerged between the quality of the psychedelic experience and symptom reduction, and a dose-response relationship was observed. Secondary outcomes like well-being, rumination, and anxiety also improved. The non-directive therapy approach during high-dose sessions allowed personalized experiences. The review suggests psilocybin is an effective treatment for MDD, though more research is needed.